Skip to main content
. 2022 Mar 10;15:2835–2845. doi: 10.2147/IJGM.S353098

Figure 2.

Figure 2

Cumulative incidence for serious GI complications between PPI and rebamipide in (A) a high risk group (Gray’s test p-value < 0.01), (B) moderate risk group with 2 risk factors (Gray’s test p-value = 0.02), and (C) elderly patients without risk factors (Gray’s test p-value = 0.43).

Abbreviations: GI, gastrointestinal; PPI, proton-pump inhibitor.